Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

References

• Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212–222.
   PubMed Web of Science ®Google Scholar
• Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364–367.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–363.
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–1550.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996;82:79–100.
   PubMedGoogle Scholar
• Yang SH, Lin JK, Lai CR, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol. 2004;87:167–173.
   PubMed Web of Science ®Google Scholar
• Homma Y, Hamano T, Akazawa Y, et al. Positive peritoneal washing cytology is a potential risk factor for the recurrence of curatively resected colorectal cancer. Surg Today. 2014;44:1084–1089.
   PubMed Web of Science ®Google Scholar
• Honore C, Goere D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–192.
   PubMed Web of Science ®Google Scholar
• Uras C, Altinkaya E, Yardimci H, et al. Peritoneal cytology in the determination of free tumour cells within the abdomen in colon cancer. Surg Oncol. 1996;5:259–263.
   PubMed Web of Science ®Google Scholar
• Horattas MC, Evasovich MR, Topham N. Colorectal carcinoma and the relationship of peritoneal cytology. Am J Surg. 1997;174:334–337.
   PubMed Web of Science ®Google Scholar
• Kim SH, Milsom JW, Gramlich TL, et al. Does laparoscopic vs. conventional surgery increase exfoliated cancer cells in the peritoneal cavity during resection of colorectal cancer? Dis Colon Rectum. 1998;41:971–978.
   PubMed Web of Science ®Google Scholar
• Wind P, Norklinger B, Roger V, et al. Long-term prognostic value of positive peritoneal washing in colon cancer. Scand J Gastroenterol. 1999;34:606–610.
   PubMed Web of Science ®Google Scholar
• Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768–775.
   PubMed Web of Science ®Google Scholar
• Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg. 2003;90:882–888.
   PubMed Web of Science ®Google Scholar
• Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum. 2003;46:535–539.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Akasu T, Fujita S, et al. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol. 2003;33:33–37.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Watanabe T, Sunami E, et al. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer. Dis Colon Rectum. 2009;52:2016–2021.
   PubMed Web of Science ®Google Scholar
• Noura S, Ohue M, Seki Y, et al. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum. 2009;52:1312–1320.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Iinuma H, Aoyagi Y, et al. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery. Oncology. 2010;78:309–315.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Cohen AM, Hajdu S, et al. Serosal cytologic study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer. 1992;70:737–740.
   PubMed Web of Science ®Google Scholar
• Ojima H, Sasaki S, Fujisawa T, et al. Utility of serosal stamp cytology as an indicator for high-risk peritoneal metastasis in colorectal cancer surgery. Hepatogastroenterology. 2003;50:87–90.
   PubMedGoogle Scholar
• Baskaranathan S, Philips J, McCredden P, et al. Free colorectal cancer cells on the peritoneal surface: correlation with pathologic variables and survival. Dis Colon Rectum. 2004;47:2076–2079.
   PubMed Web of Science ®Google Scholar
• Cotte E, Peyrat P, Piaton E, et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol. 2013;39:707–714.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12:703–27, xiii.
   PubMedGoogle Scholar
• Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384:576–587.
   PubMed Web of Science ®Google Scholar
• Piso P, Glockzin G, Von BP, et al. Patient selection for a curative approach to carcinomatosis. Cancer J. 2009;15:236–242.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649–671.
   PubMedGoogle Scholar
• Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9–15.
   PubMed Web of Science ®Google Scholar
• Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–1336.
   PubMed Web of Science ®Google Scholar
• Cashin PH, Graf W, Nygren P, et al. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:4183–4189.
   PubMed Web of Science ®Google Scholar
• Kianmanesh R, Scaringi S, Sabate JM, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245:597–603.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Zhao J, et al. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol. 2009;35:1299–1305.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–133.
   PubMed Web of Science ®Google Scholar
• Melero JT, Ortega FG, Gonzalez AM, et al. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC). Surgery. 2016;159:728–735.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–907.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.
   PubMedGoogle Scholar
• Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res. 1980;74:264–269.
   PubMedGoogle Scholar
• Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265–4269.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Gianola FJ, Barofsky I, et al. 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. Cancer. 1986;58:826–831.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50:5790–5794.
   PubMed Web of Science ®Google Scholar
• Yu WS, Sugarbaker PH. Early postoperative intraperitoneal chemotherapy for gastric cancer. Cancer Treat Res. 1991;55:265–275.
   PubMedGoogle Scholar
• Morgan RJ Jr, Synold TW, Xi B, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13:1232–1237.
   PubMed Web of Science ®Google Scholar
• Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren. 2005;288:F433–F442.
   PubMed Web of Science ®Google Scholar
• Flessner M, Henegar J, Bigler S, et al. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit Dial Int. 2003;23:542–549.
   PubMed Web of Science ®Google Scholar
• de Lima Vazquez V, Stuart OA, Mohamed F, et al. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52:108–112.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–3214.
   PubMed Web of Science ®Google Scholar
• Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–165.
   PubMed Web of Science ®Google Scholar
• El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117–127.
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351–1381.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer. 1977;39:2637–2646.
   PubMed Web of Science ®Google Scholar
• Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–260.
   PubMed Web of Science ®Google Scholar
• Koga S, Shimizu N, Maeta M, et al. Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system). Gan To Kagaku Ryoho. 1983;10:358–365.
   PubMedGoogle Scholar
• Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40:1165–1168.
   PubMed Web of Science ®Google Scholar
• Wallner KE, Li GC. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res. 1987;47:493–495.
   PubMed Web of Science ®Google Scholar
• Fernandez-Trigo V, Stuart OA, Stephens AD, et al. Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Cancer Treat Res. 1996;81:51–61.
   PubMedGoogle Scholar
• Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21:681–687.
   PubMed Web of Science ®Google Scholar
• Dahl O, Dalene R, Schem BC, et al. Status of clinical hyperthermia. Acta Oncol. 1999;38:863–873.
   PubMed Web of Science ®Google Scholar
• Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.
   PubMedGoogle Scholar
• Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431–442.
   PubMed Web of Science ®Google Scholar
• Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984;44:605–612.
   PubMed Web of Science ®Google Scholar
• Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006;22:191–196.
   PubMed Web of Science ®Google Scholar
• Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA. 1975;72:937–940.
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Holden SA, Ara G, et al. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia. 1995;11:575–586.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463–468.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Takahashi M, Kobayashi K, et al. Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer. 1992;70:2754–2760.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stuart OA, et al. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–154.
   PubMed Web of Science ®Google Scholar
• Piche N, Leblond FA, Sideris L, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138–144.
   PubMed Web of Science ®Google Scholar
• Van ME. Rhone-Poulenc-Rorer fellowship travel report 1996. A report of a study trip in relation to the HIPEC-procedure, a current treatment for abdominal carcinomas. Oncologica. 1997;14:10–15.
   Google Scholar
• Zoetmulder FA, Van D V, Witkamp AJ, et al. Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute. Ned Tijdschr Geneeskd. 1999;143:1863–1868.
   PubMedGoogle Scholar
• Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2:68–75.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Dominique E, Baratti D, et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247–252.
   PubMed Web of Science ®Google Scholar
• Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21:1501–1505.
   PubMed Web of Science ®Google Scholar
• Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12:755–69, xiv.
   PubMedGoogle Scholar
• Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703–708.
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–272.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10:112–122.
   PubMed Web of Science ®Google Scholar
• Losa F, Barrios P, Salazar R, et al. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol. 2014;16:128–140.
   PubMed Web of Science ®Google Scholar
• Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685.
   PubMed Web of Science ®Google Scholar
• Casado-Adam A, Alderman R, Stuart OA, et al. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011;2011:468698.
   PubMedGoogle Scholar
• Quenet F, Goere D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.
   PubMed Web of Science ®Google Scholar
• Gardner SN. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Res. 2000;60:1417–1425.
   PubMed Web of Science ®Google Scholar
• Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240:278–285.
   PubMed Web of Science ®Google Scholar
• Sangisetty SL, Miner TJ. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87–95.
   PubMedGoogle Scholar
• Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21:1474–1479.
   PubMed Web of Science ®Google Scholar
• Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43:237–250.
   PubMed Web of Science ®Google Scholar
• De Gramont GA, Tournigand C, Louvet C, et al. Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD. Rev Med Internet. 1997;18:769–775.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Vidal-Jove J, Steves MA, et al. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113:631–636.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–138.
   PubMed Web of Science ®Google Scholar
• Elias D, Benizri E, Di PD, et al. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:509–514.
   PubMed Web of Science ®Google Scholar
• Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:106–112.
   PubMed Web of Science ®Google Scholar
• Robella M, Vaira M, De SM. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.
   PubMed Web of Science ®Google Scholar
• Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7:18–28.
   PubMed Web of Science ®Google Scholar
• Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–439.
   PubMedGoogle Scholar
• Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242–246.
   PubMed Web of Science ®Google Scholar
• Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–796.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Yonemura Y, Fujita H, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg. 1999;84:60–66.
   PubMed Web of Science ®Google Scholar
• Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology. 1999;57:106–114.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol. 2005;92:142–146.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Stuart OA, Chang D, et al. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7:596–603.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Van RS, De BE, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–2432.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.
   PubMed Web of Science ®Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–3292.
   PubMed Web of Science ®Google Scholar
• Hompes D, D’Hoore A, Van CE, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol. 2012;19:2186–2194.
   PubMed Web of Science ®Google Scholar
• Kwakman R, Schrama AM, Van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102–1111.
   PubMed Web of Science ®Google Scholar
• Goere D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–2964.
   PubMed Web of Science ®Google Scholar
• Chia CS, Tan GH, Lim C, et al. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2905–2913.
   PubMed Web of Science ®Google Scholar
• Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:772–783.
   PubMed Web of Science ®Google Scholar
• Hamilton TD, Taylor EL, Cannell AJ, et al. Impact of major complications on patients’ quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2946–2952.
   PubMed Web of Science ®Google Scholar
• Kuijpers AM, Mehta AM, Boot H, et al. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol. 2014;25:864–869.
   PubMed Web of Science ®Google Scholar
• Devilee RA, Simkens GA, Van Oudheusden TR, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2841–2848.
   PubMed Web of Science ®Google Scholar
• Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013;13:67.
   PubMed Web of Science ®Google Scholar
• Willaert W, Van Der Speeten K, Liberale G, et al. BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC Cancer. 2015;15:980.
   PubMed Web of Science ®Google Scholar
• Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428.
   PubMed Web of Science ®Google Scholar
• Elias D, Honore C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–293.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Iusco D, et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol. 2017;24:167–175.
   PubMed Web of Science ®Google Scholar
• Pinto A, Eveno C, Pocard M. Update on clinical trials in colorectal cancer peritoneal metastasis. Int J Hyperthermia. 2017 Aug;33(5):543-547.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier:NCT01226394. 2017. https://clinicaltrials.gov/ct2/show/NCT01226394.
   Google Scholar
• Gelli M, Hugueinin JF, Cerebelli C, et al. Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. Future Oncol. 2017;13:907–918.
   PubMed Web of Science ®Google Scholar